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HIV replication within tissues may increase in response to a reduced exposure to antiretroviral drugs. Traditional 
approaches to measuring drug concentrations in tissues are unable to characterize a heterogeneous drug distri-
bution. Here, we used mass spectrometry imaging (MSI) to visualize the distribution of six HIV antiretroviral drugs 
in gut tissue sections from three species (two strains of humanized mice, macaques, and humans). We measured 
drug concentrations in proximity to CD3+ T cells that are targeted by HIV, as well as expression of HIV or SHIV RNA 
and expression of the MDR1 drug efflux transporter in gut tissue from HIV-infected humanized mice, SHIV-infected 
macaques, and HIV-infected humans treated with combination antiretroviral drug therapy. Serial 10-m sections 
of snap-frozen ileal and rectal tissue were analyzed by MSI for CD3+ T cells and MDR1 efflux transporter expression 
by immunofluorescence and immunohistochemistry, respectively. The tissue slices were analyzed for HIV/SHIV 
RNA expression by in situ hybridization and for antiretroviral drug concentrations by liquid chromatography–
mass spectrometry. The gastrointestinal tissue distribution of the six drugs was heterogeneous. Fifty percent to 
60% of CD3+ T cells did not colocalize with detectable drug concentrations in the gut tissue. In all three species, 
up to 90% of HIV/SHIV RNA was found to be expressed in gut tissue with no exposure to drug. These data suggest 
that there may be gut regions with little to no exposure to antiretroviral drugs, which may result in low-level HIV 
replication contributing to HIV persistence.
INTRODUCTION
The persistence of HIV despite treatment with combination anti­
retroviral therapy is the major obstacle to eradication of this disease, 
necessitating lifelong therapy in HIV­infected individuals. Rebound 
plasma viremia after treatment cessation is thought to be secondary 
to reactivation of latently infected memory T cell populations (1–4). 
However, it has been hypothesized that residual HIV replication 
from productively infected T cells within tissue reservoirs may also 
contribute to viral rebound upon treatment interruption (5).
The evidence for continued production of replication­competent 
virions within certain anatomical sites has been extensively reviewed 
(6, 7). Several tissue compartments, such as the central nervous system 
(8), male and female genital tracts (9, 10), peripheral lymph nodes 
(11), and gut­associated lymphoid tissue (GALT) (10), have been 
implicated as potential tissue reservoirs and have recently been 
characterized in nonhuman primate (NHP) models (12). The conse­
quences of persistent active HIV replication in GALT, such as prolonged 
immune dysregulation and incomplete CD4+ T cell reconstitution 
during combination antiretroviral therapy, are different from the 
consequences in other anatomical compartments (13). The mechanisms 
underlying HIV persistence in tissue reservoirs like GALT are unclear, 
but suboptimal antiretroviral drug penetration into tissues has 
been suggested as one potential cause (14). Inadequate tissue ex­
posure to antiretroviral drugs may explain the persistence of HIV 
replication.
Traditional methods for measuring the penetration of small 
molecules into tissues are limited in their capacity to measure hetero­
geneity of drug distribution within tissues. Liquid chromatography– 
mass spectrometry (LC­MS) analysis of tissue homogenates has been 
the gold standard for antiretroviral drug tissue analysis but provides 
only an aggregate concentration of drug over the entire tissue. If 
HIV replication occurs focally, for example, in a single lymphoid 
follicle, LC­MS analysis may not accurately represent antiretroviral 
drug concentrations at the site of action. Some groups have isolated 
mononuclear cell populations from tissues before performing LC­MS 
(14). Although this method is an improvement over analysis of tissue 
homogenates, it does not fully account for drug lost during mononuclear 
cell isolation (15) and cannot distinguish between mononuclear cell 
populations from different sites within the tissue.
Mass spectrometry imaging (MSI) can be used to quantitate small 
molecules at discrete tissue sample locations while maintaining 
spatial information across the entirety of a sectioned tissue sample, 
which allows the analyte distribution within a sample to be visualized 
(16, 17). An advantage of MSI is the ability of this method to spatially 
correlate antiretroviral drug distribution with sites of potential HIV 
replication in serial tissue sections. Focal HIV RNA expression in 
tissue areas with low antiretroviral drug concentrations could indi­
cate areas where there is active viral replication.
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In addition to advancing our understanding of how antiretroviral 
drugs become distributed in tissues, MSI can provide information 
about whether antiretroviral drug distribution in tissues differs 
among preclinical animal models and between animals and humans. 
Although the development of any new therapeutic agent requires 
testing in animal models, efficacy end points may differ if the within­ 
tissue drug distribution is different be­
tween the animal models and humans.
Here, we used MSI to visualize the 
distribution of antiretroviral drugs from 
several therapeutic classes in gastro­
intestinal tissues from HIV­infected 
humanized mice, SHIV (simian/human 
immunodeficiency virus)–infected ma­
caques, and HIV­infected human sub­
jects. We assessed the colocalization 
of antiretroviral drugs with HIV target 
cells and viral RNA expression. Then, 
we determined the extent to which 
antiretroviral drug distribution was 
associated with potential sites of viral 
replication. We also evaluated antiret­
roviral drug distribution in the context 
of drug efflux transporter expression by 
gut epithelial cells.
RESULTS
Demographics of patients in 
clinical study
Between April 2016 and August 2017, a 
total of five HIV­infected women taking 
some combination of tenofovir disoproxil 
fumarate/emtricitabine, efavirenz, ataza­
navir, raltegravir, and maraviroc com­
pleted the clinical study (NCT02641444; 
summary demographics are shown in 
table S1). Participants had a median age 
of 53 years and a median body mass 
index (BMI) of 39.1; four of five women 
were African­ American. Menopause sta­
tus was evenly distributed with two women 
premenopause and three women post­
menopause. All five participants had been 
HIV positive for >5 years (median, 18 years) 
and had been on their current combina­
tion antiretroviral drug therapy regimen 
for a median of 8 years. Participants had 
well­controlled HIV infection as evi­
denced by undetectable (<50 copies/ml) 
plasma viremia and high CD4 T cell 
counts (median, 753 cells/mm3). A single 
adverse event (grade 1 headache) was 
observed.
Antiretroviral drug penetration in 
ileal and rectal tissue
Plasma and tissue combination antiret­
roviral therapy concentrations measured 
by LC­MS in this study and our previous study (18) were used to 
generate tissue penetration ratios for each drug in ileum and rec­
tum biopsies obtained by colonoscopy from five HIV­infected par­
ticipants (table S2). In human ileum tissue, penetration of tenofovir was 
>10 times higher compared to ileum tissue in mice or NHPs (P = 
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Fig. 1. Antiretroviral drug distribution in gut tissue from three species. Representative images of antiretroviral 
drug distribution in a single cross-sectional 10-m slice of ileum from an uninfected macaque, an HIV-infected 
humanized BLT mouse, and an HIV-infected human measured using MSI are shown. A total of 24 macaques, 98 mice, 
and 10 human tissue slices were imaged by MSI. (A to J) Macaque. (K to N) Mouse. (O to V) Human. Relative drug 
abundance is indicated by the color scale: Lighter colors (yellow and white) are associated with higher drug concen-
trations than darker colors (red and black). Endogenous cholesterol distribution is shown in macaque ileum in (A) to 
demonstrate tissue orientation for the remaining images. Drug distribution images for all antiretroviral drugs admin-
istered to this macaque (B to E) are overlaid with the localization of CD3+ T cells from an adjacent tissue section (F), 
and the colocalization is shown in (G) to (J) (drug, red; CD3+ T cells, green). Similar images of antiretroviral drug 
(tenofovir) concentration on its own or overlaid with CD3+ T cell localization are shown for an HIV-infected BLT 
mouse (K to N) and an HIV-infected human (O to V). Scale bars to the left of each endogenous cholesterol image apply 
to all antiretroviral drug distribution images for that tissue slice. In the BLT mouse ileum slice (K and L), tenofovir was 
the only drug detected by MSI and was overlaid with the CD3+ T cell image (N). In the human ileum tissue section 
(O to R), all three drugs contained in the patient’s antiretroviral drug regimen were detected by MSI. (T) to (V) show 
these images overlaid with CD3+ T cell localization (S).
raltegravir, and maraviroc into human ileum was two­ to sevenfold 
higher compared to the ileum of mice (P < 0.05) and was similar 
to penetration of the ileum of NHPs (table S2) (18). Penetration of 
tenofovir into the human rectum was >10 times greater compared 
to the rectum of mice (P = 0.003). Penetration of efavirenz, atazanavir, 
raltegravir, and maraviroc was 2­ to 10­fold higher in human rectum 
compared to mouse rectum (P < 0.05) and was similar to the penetra­
tion into the rectum of NHPs (table S2) (18).
Heterogeneous antiretroviral drug distribution  
in gut tissue from three species
Heterogeneous distribution of antiretroviral drugs was observed 
in 10­m gut tissue sections from two strains of humanized mice, 
12 macaques (6 uninfected and 6 SHIV­infected) and 5 HIV­infected 
humans. Representative images of antiretroviral drug distribution 
in the three species are shown in Fig. 1. Images of endogenous choles­
terol were included to delineate tissue orientation (Fig. 1A). In un­
infected macaques, tenofovir (Fig. 1B) and emtricitabine (Fig. 1C) 
showed disparate drug distribution patterns, with tenofovir having 
the highest signal in the lumen of the ileum, and low but consistent 
penetration into the mucosa and outer muscle layer of the ileum. In 
contrast, emtricitabine concentrations were below the detection limit 
of our MSI technique. Consistent with our previously published 
data (19), the distribution of efavirenz was heterogeneous through­
out the ileum and rectum of uninfected macaques and was localized 
primarily to the mucosal layer (Fig. 1D). Conversely, raltegravir was 
localized to the lumen of the ileum and rectum of uninfected 
macaques with less penetration into the mucosal layer (Fig. 1E). We 
next investigated the localization of CD3+ T cells in the ileum and 
rectum of uninfected macaques (Fig. 1, G to J). Fourteen percent to 
29% of all cells in the macaque ileum were calculated to be CD3+ 
T cells (Fig. 1F). Differences between the distribution of antiretroviral 
drugs and the localization of CD3+ T cells were observed in the un­
infected macaque ileum and rectum.
Representative images of the gut tissue distribution of tenofovir 
in an HIV­infected humanized mouse are shown in Fig. 1 (K to N). 
Compared to uninfected macaque gut tissues, antiretroviral drug 
distribution was more heterogeneous in the gut tissue of two 
humanized mouse strains: the hu­HSC­Rag (n = 36) and bone marrow– 
liver–thymus (BLT) (n = 13) humanized mouse models. Raltegravir 
and emtricitabine could not be detected by infrared matrix­assisted 
laser desorption electrospray ionization (IR­MALDESI) in any gut 
tissue slices from either strain of humanized mouse, despite detection 
of drug concentrations in mouse plasma and tissue by LC­MS. We 
observed fewer detectable human CD3+ T cells in the HIV­infected 
humanized mouse gut tissue samples (1 to 3% of cells were CD3+ T cells; 
Fig. 1M) due to the limited reconstitution of human T cells into this 
compartment, particularly in the case of the hu­HSC­Rag mice (20). 
Figure 1N shows the overlay of tenofovir with CD3+ T cells, reveal­
ing that the low tenofovir signal had limited colocalization with the 
signal for CD3+ T cells.
Representative images for antiretroviral drug distribution in gut 
biopsies from HIV­infected individuals are shown in Fig. 1 (O to V). 
There were detectable concentrations of tenofovir and emtricitabine 
in the plasma (tenofovir, 36 to 236 ng/ml; emtricitabine, 63 to 
612 ng/ml) and gut tissue biopsies (tenofovir, 1596 to 17,820 ng/g; 
emtricitabine, 146 to 2762 ng/g) measured by LC­MS. However, 
concentrations of these two drugs could only be detected sporadi­
cally in the gut biopsy samples by MSI, even before correcting for 
potential blood contamination using heme. In contrast, efavirenz, 
raltegravir, atazanavir, and maraviroc were detected in all human 
ileal and rectal biopsy samples with a broad distribution throughout 
the mucosa and submucosa.
Given that these drugs are given in combination for maximal 
antiviral efficacy, we combined discrete maps of antiretroviral drug 
distribution to visualize overall drug concentrations in macaque 
gut tissue and then inspected the overlap with the localization 
of CD3+ T cells (Fig. 2). Figure 2 shows representative MSI images 
assessing the extent to which antiretroviral drug combinations 
colocalized with CD3+ T cell expression measured in adjacent tissue 
sections of a single SHIV­infected macaque ileum. MSI images for 
each anti retroviral drug in the same tissue slice are shown in Fig. 2 
(A to D), with a composite image representing total drug distribu­
tion in Fig. 2E. The proportion of CD3+ T cells that colocalized 
with each drug is shown in Fig. 2 (G to I), and the proportion of 
CD3+ T cells colocalizing with any of the antiretroviral drugs is 
shown in Fig. 2J. In this tissue slice, about 60% of CD3+ T cells co­
localized with the distribution of either maraviroc or atazanavir, 
leaving 40% of the cell population unexposed to drug or exposed 
to drug concentrations below the limit of detection (LOD) (estimated 
MSI LODs: 708 fg per voxel for maraviroc 
and 1428 fg per voxel for atazanavir). 
The proportion of CD3+ T cells colocal­
ized with each antiretroviral drug in il­
eal and rectal biopsies from humanized 
mice, macaques, and humans is shown 
in table S3. In both the ileum and rec­
tum, tenofovir and emtricitabine distri­
bution overlapped the least with CD3+ 
T cell localization compared to the other
antiretroviral drugs, but the variability 
was large for all species (0 to 80% cover­
age). These data were confounded by 
the lower sensitivity of MSI regarding 
detection of tenofovir and emtricitabine 
(estimated MSI LOD: 3372 fg per voxel 
for tenofovir and 5026 fg per voxel for 
emtricitabine) and did not account for 
intracellular phosphorylation of these 
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Fig. 2. Incomplete antiretroviral drug and CD3+ T cell colocalization in macaque ileum. Representative images 
of antiretroviral drug distribution in a single cross-sectional 10-m slice of ileum from an SHIV-infected macaque 
measured by MSI are shown. A total of 12 macaque ileal tissue slices were imaged by MSI. (B to D) Lighter colors 
(yellow and white) are associated with higher antiretroviral drug concentrations than darker colors (red and black). 
Endogenous cholesterol distribution is shown in (A) to demonstrate tissue orientation for the remaining images. 
(E) Composite image of the distribution of all three drugs. (G to J) These images were overlaid with the CD3+ T cell 
distribution from an adjacent ileal tissue slice (F) (drug, red; CD3+ T cells, green). The percentage of total CD3+ T cells 
colocalizing with tenofovir (G), maraviroc (H), or atazanavir (I) is shown at the bottom right of the respective panels. 
The percentage of total CD3+ T cells colocalizing with at least one drug is shown in (J).
drugs to their active metabolites (tenofovir diphosphate and emtric­
itabine triphosphate).
Table 1 summarizes the proportion of CD3+ T cells that were 
not exposed to any antiretroviral drug for the two humanized mouse 
strains, macaques, and humans. No differences were observed be­
tween infected and uninfected mice and macaques, and so, these 
data were combined for analysis. In both the ileum and rectum, ma­
caque and human showed the broadest CD3+ T cell coverage with me­
dian proportions of T cells colocalized to an antiretroviral drug of 
0.5 to 0.6 (Table 1). CD3+ T cells in the ileum and rectum of hu­HSC­
Rag mice, which represented 80% of all T cells, colocalized with 
maraviroc and atazanavir but not the other drugs (table S2). Human, 
macaque, and BLT humanized mice all had a higher proportion of 
CD3+ T cells colocalizing with each antiretroviral drug in the ileum 
and rectum than did hu­HSC­Rag mice (P < 0.01). No differences 
were seen in the distribution of CD3+ T cells between the ileum 
and rectum for any species (P > 0.05).
Correlation of viral RNA expression with antiretroviral  
drug distribution
Next, we determined whether the incomplete overlap of CD3+ 
T cells with antiretroviral drug distribution in ileum and rectum 
was associated with HIV or SHIV RNA expression in these tissues. 
MSI images of CD3+ T cell and drug distribution were co­registered 
with viral RNA images obtained from in situ hybridization (ISH) 
at matching image resolution. HIV or SHIV RNA expression was 
localized into discrete clusters within the submucosa of the ileum 
and rectum of all three species (fig. S1A, inset). Figure 3 shows rep­
resentative MSI overlay images of antiretroviral drug distribution 
and viral RNA expression in SHIV­infected macaque ileum. The 
MSI images showed areas of viral RNA expression (Fig. 3, G to J) 
that did not overlap with drug distribution (Fig. 3, B to E). How­
ever, this effect was not seen consistently with all antiretroviral 
drugs. Emtricitabine and tenofovir were found primarily where no 
viral RNA was located (Fig. 3, G and H), whereas maraviroc and 
atazanavir were found where a large proportion of viral RNA was 
expressed (Fig. 3, I and J; proportion of viral RNA colocalized to 
drug, 0.9 and 0.7, respectively).
Penetration of antiretroviral drugs into the macaque ileum as a 
function of the in vitro IC90 (90% maximal inhibitory concentration) 
values for each drug is shown in Fig. 3 (K to N). Emtricitabine and 
tenofovir were present at concentrations below their respective 
IC90 values (Fig. 3, K and L, respectively, red); very few tissue 
regions had antiretroviral drugs above this threshold (green). Given 
that the MSI LODs for emtricitabine and tenofovir were lower than 
the IC90 values, all areas of a tissue section where these drugs were 
not measured were assumed to have concentrations below the IC90. 
Conversely, maraviroc, efavirenz, and atazanavir concentrations were 
primarily above their IC90 values. The distribution of individual drugs 
localized to regions of viral RNA expression is shown in Fig. 3 (O to R). 
Many of the tissue regions where emtricitabine and tenofovir were 
colocalized with viral RNA expression were at concentrations below 
the IC90 values for these drugs; maraviroc and atazanavir concen­
trations remained above this threshold in most cases. There were, 
however, several tissue regions where maraviroc and viral RNA 
expression was colocalized at sub­IC90 concentrations of drug 
(Fig. 3Q).
Table 2 shows the extent of anti retroviral drug distribution com­
pared to viral RNA expression for HIV­infected humanized mice, 
SHIV­infected macaques, and HIV­infected human patients. Unlike 
our results for CD3+ T cell distribution, the localization of viral RNA 
expression with drug distribution was high (median values, 10 to 
100%), with the ileum and rectum of some mice demonstrating 
complete overlap for one or more anti retroviral drugs (after correction 
for potential blood contamination based on the heme b signal; Table 2). 
However, observed variability was also high, with overlap ranging 
from 0 to 100%, depending on the species (Table 2). For hu­HSC­
Rag humanized mice, viral RNA expression and drug distribution 
overlap were lower than for BLT humanized mice and macaques 
(0% versus 50 to 90%; P < 0.01; Table 2). Results in the ileum and 
rectum were similar for all species.
Table 3 summarizes the calculated concentrations for each anti­
retroviral drug closest to the region of peak viral RNA expression 
measured by MSI. These concentrations surpassed in vitro IC90 
values for most of the drugs except for tenofovir and emtricitabine, 
which were not detected in many samples. The lack of detection of 
emtrici tabine and tenofovir, which was consistent across species 
and between ileum and rectum, may reflect the limitations of MSI 
because these drugs achieved high tissue concentrations when mea­
sured with LC­MS (21, 22). Tenofovir and emtricitabine concentra­
tions in serial tissue slices were more frequently detected by LC­MS 
than by MSI but were still below their respective IC90 values. Tenofovir 
diphosphate and emtricitabine triphosphate measured by LC­MS 
showed different detection rates in ileum and rectum, with tenofovir 
diphosphate being readily detected and emtricitabine triphosphate 
being infrequently detected in the three species. Efavirenz and 
raltegravir were only sporadically detected in the humanized mice 
(efavirenz, 12%; raltegravir, 35%) despite being readily detectable 
in macaques and humans (100%) at concentrations that greatly 
exceeded reported IC90 values. Maraviroc and atazanavir were detected 
Table 1. Percent CD3+ T cells not colocalizing with any antiretroviral drug. Data are median and range. 
BLT (n = 13) hu-HSC-Rag (n = 36) Macaque (n = 12) Human (n = 5) P
Ileum 50 (10–100) 100 (20–100) 40 (10–90) 40 (30–50) <0.01
Rectum 40 (10–100) 100 (20–100) 50 (20–80) 40 (20–70) <0.01
Table 2. Percent viral RNA expression colocalizing with antiretroviral 
drug. Data are median and range. 




(n = 5)* P
Ileum 10 (0–100) 0 (0–100) 80 (40–90) 90 (80–90) <0.01
Rectum 50 (20–100) 0 (0–100) 60 (20–80)
100 
(100–100) <0.01
*Viral RNA was detected in rectal samples from only two of five women.
with the greatest frequency across species (>80%), with the highest con­
centrations detected in the ileum and rectum of mice and macaques.
Drug efflux transporter expression and  
antiretroviral drug distribution
Because drug efflux transporters are known to play a role in the 
tissue distribution of antiretroviral drugs and have been previously 
quantified in mouse and macaque tissues (18), we next assessed the 
potential impact of these efflux transporters by evaluating their 
distribution compared to the distribution of antiretroviral drugs 
as quantified by Pearson correlations. Figure 4 shows representative 
images of the overlap in antiretroviral drug distribution and multi­
drug resist ance protein 1 (MDR1) efflux transporter expression in 
mouse, macaque, and human ileum. Figure 4 (B to E) shows heme­ 
corrected MSI images for four different drugs, each showing a distinct 
distribution pattern in uninfected macaque ileum. When assessed 
in vitro in a previous study, raltegravir, atazanavir, and maraviroc 
showed affinity for MDR1 efflux transporter proteins (23). In this 
study, efavirenz distribution did not appear to be affected by the 
expression or localization of MDR1 efflux transporters in macaque 
ileum, because the two variables were not colocalized (r = 0.02; 
Fig.  4I); efavirenz appeared to have crossed the gut mucosa and 
accumulated in adipose tissue. Conversely, raltegravir accumulated 
on the luminal surface of the macaque ileum mucosa with limited 
penetration into the submucosa (Fig. 4E) 
and colocalized moderately with MDR1 
efflux transporters (r = 0.3; Fig. 4J). 
Similarly, tenofovir (Fig. 4B) showed colo­
calization with MDR1 efflux transporters 
(Fig. 4G) in macaque ileum despite a 
lack of evidence supporting tenofovir as 
a substrate for these proteins.
Representative images of ileum tissue 
slices from HIV­infected mice and HIV­ 
infected humans are shown in Fig. 4 
(K to N and O to V, respectively). MDR1 
efflux transporter expression was detected 
extensively along the luminal surface of 
mouse gut epithelial cells with low­to­ 
moderate colocalization with antiretro­
viral drugs (r range, −0.1 to 0.5).
DISCUSSION
Here, we assessed the distribution of 
antiretroviral drugs in gut tissues across 
three species and measured the distribu­
tion relative to CD3+ T cells and ex­
pression of HIV or SHIV RNA. Despite 
dosing with combination drug therapy 
to a pharmacokinetic steady state, 40 to 
60% of CD3+ T cells remained unexposed 
to antiretroviral drugs in gut samples 
from all three species. The limitations of 
using conventional methods for small­ 
molecule quantitation in tissue (e.g., 
LC­MS analysis of whole tissue homo­
genates) have been acknowledged pre­
viously (15, 24), and different models 
of heterogeneous antiretroviral drug distribution in tissue have 
been proposed (5). Our data highlight the advantages of using MSI 
for characterizing tissue pharmacology. We have shown here that 
antiretroviral drug exposure in some areas where HIV target cells 
reside may be very small. This is particularly relevant when drawing 
inferences about target concentrations for antiretroviral drug effi­
cacy, because any proposed drug concentration would need to be 
achieved in every HIV­infected cell or HIV target cell.
Our use of CD3+ T cells to assess antiretroviral drug exposure in 
the entire T cell population versus a more targeted evaluation of 
CD4+ T cells is a major limitation of our study. Our approach over­
estimated the number of actual HIV­infected cells or HIV target 
T cells. Our attempts to identify the smaller CD4+ T cell subset were 
complicated by a high background signal that made discrete cellular 
identification impossible. However, given that about 50% of the 
CD3+ T cell population did not appear to be exposed to antiretroviral 
drug and CD4+ T cells represent about 50% of the total T cell popu­
lation in the gut mucosa (25, 26), we predict that some of these 
unexposed T cells were also CD4+ T cells. This assumption is supported 
by our data showing that viral RNA expression occurred in discrete 
clusters spread throughout lymphoid aggregates within the ileum 
and rectum of all three species. Our finding of viral gene expression 
in the gut during antiretroviral drug therapy is consistent with pre­
vious publications (27, 28) and is not surprising given the relatively 
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Fig. 3. Antiretroviral drug concentrations and SHIV RNA expression. (B to E) Representative images of the distri-
bution of four antiretroviral drugs in a single cross-sectional 10-m slice of ileum from an SHIV-infected macaque 
measured by MSI. A total of 24 macaque tissue slices were imaged by MSI. Lighter colors (yellow and white) are asso-
ciated with higher drug concentrations compared to darker colors (red and black). Endogenous cholesterol distribution 
is shown in (A) to enable tissue orientation for the remaining images. Images in (B) to (E) were overlaid (G to J) with a 
viral RNA image at matched spatial resolution from an adjacent slice (F) (drug, red; viral RNA, cyan). The percentage 
of total viral RNA colocalizing with drug is shown in the bottom left corner of each image. (K to N) Images show the 
distribution of each antiretroviral drug as a function of the drug’s IC90 value (concentrations above the IC90, green; 
concentrations below the IC90, red). (O to R) Similar analysis for drug that colocalizes with viral RNA.
short duration of drug treatment administered to the mice and 
macaques in our study. However, our study design was such that we 
could identify all potential areas of viral replication early during drug 
treatment in the animals and could determine overlap with drug 
concentrations. Future work will need to evaluate the relationship 
between drug exposure and viral gene expression in gut tissues after 
long­term suppression of plasma HIV RNA by antiretroviral drug 
therapy. We attempted to address this limitation by examining gut 
samples from HIV­infected women who had been on combined anti­
retroviral drug therapy for at least 5 years and who showed suppres­
sion of viral loads for more than 1 year. Viral RNA was detected in 
two of five rectum samples, where 100% of viral RNA was colocalized 
with at least one drug. We found that antiretroviral drugs, when 
detectable, were well above reported in vitro IC90 values, suggesting 
that the drug concentrations may have been sufficient to inhibit 
HIV/SHIV replication. However, because the drug distributions were 
not homogeneous and T cells moved within tissues, viral replication 
could still have occurred.
The lack of virus detection in plasma or development of drug 
resistance during prolonged combined antiretroviral drug therapy 
in many HIV­infected patients does not support the local tissue 
viral replication hypothesis (29). It is possible that ongoing viral 
replication occurs in small pockets of gut tissue and is held in check 
by high antiretroviral drug concentrations in other tissue regions or 
in plasma. This is supported by several studies demonstrating the 
detection of replication­competent HIV DNA in a wide array of tissues 
collected from HIV­infected patients on combined antiretroviral drug 
therapy with a suppressed plasma viral load (30, 31). Whereas HIV 
DNA is a more relevant marker of the latent HIV reservoir, it cannot 
be ruled out that some proportion of this DNA is undergoing tran­
scription to RNA and eventually is being translated into viral proteins. 
Given the widespread detection of HIV DNA in tissues, if even a 
small proportion (<1%) of total HIV DNA led to production of replication­ 
competent virions, then our hypothesis that viral replication occurred 
in isolated pockets of gut tissue surrounded by efficacious concen­
trations of antiretroviral drugs would be reasonable.
With our MSI approach, we only captured a static point in time, 
which did not reflect the dynamic movement of T cells within GALTs. 
These T cells might be exposed to adequate drug concentrations as 
they migrate through GALTs, but as they move from areas of high 
to low drug concentrations, they may end up exposed to much lower 
intracellular drug concentrations. A future goal of our work is to 
use MSI to capture intracellular concentrations of antiretroviral drugs 
in individual T cells.
Although our detection of efavirenz, atazanavir, maraviroc, and 
raltegravir in gut tissues from three species was robust, we were un­
able to adequately determine the distribution of tenofovir and 
emtricitabine, which did not exceed their respective IC90 values in 
most gut samples that we examined. Given that the sensitivity of 
our MSI method was lower for tenofovir and emtricitabine than the 
other antiretroviral drugs we tested, these data must be interpreted 
with caution. In addition, the active intracellular metabolites of these 
compounds (tenofovir diphosphate and emtricitabine triphosphate) 
could not be quantified by MSI because preparing tissue slices re­
sulted in their degradation. Therefore, although we quantified these 
drug metabolites by LC­MS, we did not know the spatial resolution 
of these drug metabolites in the gut tissue samples. Possibly, these 
drug metabolites were present in greater abundance and in different 
distribution patterns than their parent compounds. This may be the 
case as in a previous study tenofovir diphosphate and emtricitabine 
triphosphate gut concentrations were high enough after daily oral 
administration to prevent rectal sexual transmission of HIV (32). 
Because MSI technology continues to evolve, we anticipate that our 
detection limits for these drugs will improve, as will our ability to 
measure stable drug metabolite concentrations in tissues without 
compromising their distribution.
Our work also shows the potential contribution of drug efflux 
transporter protein expression in the gut to differences in antiretroviral 
Table 3. Drug concentrations proximate to viral RNA. Data are median and range. Conversion from ng/ml to ng/g was performed using an assumed tissue 
density of 1.06 g/ml. IC90 values for each drug are reported from the following references: tenofovir (55), tenofovir diphosphate (56), emtricitabine (57), 
emtricitabine triphosphate (58), efavirenz (59), maraviroc (60), atazanavir (61), raltegravir (62). ND, analyte not detected in any tissue; TFV, tenofovir; TFVdp, 







All macaques All humans
Mice
All macaques All humansBLT hu-HSC-Rag BLT hu-HSC-Rag
TFV 49 (0–1,782) 0 (0–93) 97 (0.4–151) 0 (0–340) 844 (0–1,499) 0 (0–5,152) 80 (0–182) 0 (0–158) 2,980
TFVdp* 1.7 (0–4.1) 0.8 (0–7) 0.4 (0.03–2.8) 21 (11–65) 0.003 (0–0.1) 0.07 (0–11) 0.2 (0.03–17)
17 
(9.4–23) 1.7
FTC 0 (0–96) ND 70 (1–206) ND 0 (0–37) 0 (0–41) 0 (0–66) 0 (0–6) 84
FTCtp* 0.09 (0–0.2) ND 0.02 (0.005–0.05) 0.7 (0.1–6.5) ND ND 0.001 (0–0.2)
3.3 
(1.7–7.7) 2.8
RAL ND ND 12,887 (4,420–21,353) 18,632 ND ND 6,891 (2,877–10,906) 387 10
EFV ND 358 (215–501) 24,687 0 (0–21) 385 (268–501) 15,178 10





ATZ 2,972 (0–28,616) 0 (0–117,819) 1,987 (1,152–3,674) ND 596 (0–2,794) 0 (0–23,632)
1,068 
(980–8,861) 1,832 11
*Tenofovir diphosphate and emtricitabine triphosphate concentrations (detected by LC-MS) and IC90 values are reported as ×105 fmol/g of tissue.
drug distribution. There were different degrees of colocalization of 
MDR1 efflux transporter protein expression with the different an­
tiretroviral drugs (Fig. 4). For example, the higher colocalization of 
MDR1 with raltegravir suggested that the MDR1 transporter may 
have acted as a barrier to raltegravir distribution into the gut mucosa 
from the gut lumen (33, 34). The MDR1 efflux transporter appeared 
to be less important for efavirenz distribution as indicated by the 
lower colocalization and lower concentration of efavirenz in the gut 
submucosa. Raltegravir, but not efavirenz, is a known substrate for 
the MDR1 efflux transporter (35). With the small number of mice 
and macaques investigated in this study and the large inter­animal 
variability in MDR1 transporter expression, the colocalization data 
were often not statistically significant (P > 0.05).
Previous work has shown that HIV infection can alter expression 
of drug transporters by as much as threefold (36) and that HIV 
infection can alter several pharmacokinetic variables such as intestinal 
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Fig. 4. Colocalization of antiretroviral drugs with MDR1 efflux transporter expression in three species. Representative images of antiretroviral drug distribution in 
a single cross-sectional 10-m slice of ileum from an uninfected macaque, an HIV-infected humanized BLT mouse, and an HIV-infected human are shown. A total of 
24 macaque, 98 mouse, and 10 human tissue slices were imaged by MSI. Antiretroviral drug concentrations in (B) to (E) are indicated by the color scale on the left: Lighter 
colors (yellow and white) are associated with higher drug concentrations compared to darker colors (red and black). Endogenous cholesterol distribution is shown in 
(A) to demonstrate tissue orientation for the remaining images. Images (B) to (E) were overlaid with images of MDR1 efflux transporter expression in an adjacent tissue 
slice (F). (G to J) Overlaid images show drug in red and MDR1 transporter in green. Pearson correlation coefficients (r) between these variables are listed in the bottom left 
corner of each overlaid image. Images of drug distribution alone or overlaid with MDR1 expression are shown for a BLT HIV-infected mouse (J to M) and an HIV-infected 
human (N to U). Scale bars to the left of each endogenous cholesterol image apply to all antiretroviral drug distribution images from that tissue slice. In the BLT mouse 
ileum slice shown in (K) and (L), maraviroc was the only drug detected by MSI and is shown overlaid with MDR1 expression (N). In the human ileum tissue section shown 
in (O) to (R), all three drugs contained in the patient’s antiretroviral regimen were detected by MSI. Images of drug distribution are overlaid with MDR1 expression 
(S) in (T) to (V).
absorption and drug metabolism that may affect antiretroviral drug 
distribution in tissues (37). Although the antiretroviral drugs exam­
ined here are known to use several of the drug efflux transporters 
that are altered during infection (e.g., raltegravir by MDR1), HIV/
SHIV infection did not contribute substantially to drug distribution 
in ileal or rectal tissues in our study. It is possible that our animals 
were not infected for long enough for these changes to become 
apparent (36), but our data do suggest that uninfected animals can 
be used to assess antiretroviral drug distribution.
Our study has a number of limitations including the technological 
limitations of MSI and the need for markers of antiretroviral drug 
efficacy. We generated data from 10­m tissue slices. The lack of 
antiretroviral drug detection in some of these tissue slices despite 
detection with traditional LC­MS methods can be explained by the 
decreased sensitivity of the IR­MALDESI instrumentation that we 
used. The relationship between sensitivity and image spatial resolu­
tion when using MSI has been noted (24). Compared to LC­MS, the 
LODs for IR­MALDESI for antiretroviral drugs in tissues are up to 
10­fold higher, resulting in decreased sensitivity for detection of
some antiretroviral drugs. The inherent decrease in sensitivity with
MSI can be explained, in part, by the small tissue area ablated with
each laser pulse. Given that each laser pulse ablates a 100­m area at 
10­m thickness, the tissue volume per analysis is up to 100­fold
less than that analyzed by LC­MS using tissue homogenates. In
addition, although we demonstrated that tissue architecture could
be identified in each tissue slice, our limited sampling of gut tissue
may have led to some drug distribution being overlooked. We collected
tissues at the end of the drug dosing interval, but tissue penetration
of antiretroviral drugs may have been higher or more homogeneous at
other pharmacokinetic time points. However, we minimized any
sampling confounding by dosing mice and monkeys with drug to
plasma steady­state conditions. Total tissue drug concentrations under
steady­state conditions are less variable across the dosing interval
compared to plasma and so are less likely to differ based on the time 
of tissue collection (38, 39).
At sampling locations where potential blood contamination was 
present, we used MSI detection of the blood marker heme b to correct 
our measurements. This may have resulted in an overcorrection 
particularly in mouse and human tissues. We attempted to correct 
this by applying this blood contamination correction to MSI, immuno­
histochemistry (IHC), and ISH images. The potential contribution 
from remnant blood to antiretroviral concentrations measured in 
tissue homogenates further illustrates the limitation of using LC­MS 
to measure drug concentrations, because there is no capacity to 
assess proportional antiretroviral drug concentrations in blood by 
this method.
Although the RNAscope ISH method used here has improved 
specificity compared to traditional ISH for detecting HIV/SHIV­ 
specific gene expression (40) and the frequency of viral RNA­positive 
cells may be in good agreement with fluorescence detection of 
virus­producing cells (41), the aggregate viral RNA detection we 
obtained may overestimate viral replication by capturing virions 
trapped on follicular dendritic cells in B cell follicles. Further, the 
association between cell­associated RNA measured before drug 
treatment interruption and timing of viral rebound has been demon­
strated in other studies (41), but we were not able to discriminate 
between cell­associated RNA and free virions in our study. By cor­
relating antiretroviral drug distribution to gut regions where active 
virions could be produced, our results may represent a worst­case 
scenario. We attempted to overcome this limitation by staining all 
virus­infected tissues for the viral protein markers p27 (macaque tissue) 
or p24 (humanized mice and human tissue); however, we were un­
able to detect these two viral proteins with enough signal to perform 
a robust analysis with our drug concentration data. Currently, we 
are investigating measurements of downstream components of the 
HIV life cycle by ISH and IR­MALDESI MSI.
We compared antiretroviral drug concentrations to their indi­
vidual IC90 values without consideration for the synergistic effects 
of antiretroviral drugs in combination (Table 3). The antiretroviral 
drugs evaluated here may have exceeded efficacious concentrations 
due to the presence of other active drugs at the same gut tissue loca­
tions, but we were unable to make those comparisons. This has 
direct relevance for measuring the proportion of CD3+ T cells 
exposed to at least one antiretroviral drug (Fig. 2 and table S2). Our 
analysis makes a distinction between CD3+ T cells that are not ex­
posed to drug and those that are exposed to at least one drug, but 
assessments of the whole drug combination regimen could not be 
performed. Future work will use the MSI signal from endogenous 
metabolites and lipids to segment and categorize histological features 
in each tissue (42–45) to allow for cross­experiment comparisons 
between the whole drug regimens.
The antiretroviral drug concentrations measured in this study rep­
resent total rather than unbound drug, whereas drug efficacy is 
driven by free drug concentrations at the site of action (46). The 
extent of protein binding and thus free drug concentrations can differ 
between plasma and tissues for anti­infective agents (46, 47). In 
some cases, estimates of the free drug in tissues can be accurately 
extrapolated from plasma drug concentrations (48, 49), but direct 
measurement of unbound tissue concentrations of drug provides 
the most useful data for efficacy. Strategies such as ultrafiltration or 
microdialysis have been used by others to measure unbound drug 
concentrations in tissues directly (50).
We did find some viral RNA­expressing cells in gut tissue that 
were not located close to measurable amounts of drug, despite 
adequate (>IC90) exposure elsewhere in the tissue. This does not prove 
a causal relationship between suboptimal antiretroviral drug expo­
sure and ongoing viral replication given that we likely overestimated 
both of these variables, but it does suggest the feasibility of applying 




The primary objective of this study was to use MSI to characterize 
antiretroviral drug distribution within gastrointestinal tissues from 
three animal models (two strains of humanized mice and macaques) 
and humans. The goal was to quantitatively determine whether anti­
retroviral drug exposure in gut tissue at a single time point resulted 
in areas where HIV target CD3+ T cells or viral RNA expression did 
not overlap with drug distribution. Secondary objectives included 
correlating antiretroviral drug concentrations with drug efflux 
transporter expression, interspecies comparisons of antiretroviral 
drug exposure in gut tissues, and assessment of differences in in­
fected and uninfected animals. We hypothesized that antiretroviral 
drug distribution would be heterogeneous in all three species and 
could result in tissue regions devoid of any drug. Animals were 
randomized to an antiretroviral drug treatment regimen, but human 
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subjects were selected on the basis of the regimen they were currently 
taking. No element of this study was blinded.
Animal models
We used three animal models from two species: the hu­HSC­Rag 
(n = 36) and BLT (n = 13) humanized mouse models and a rhesus 
macaque NHP model (n = 12). Detailed descriptions of the animals 
used for this study, including infection and dosing information, as 
well as plasma concentrations, have been reported elsewhere (18). 
Briefly, female humanized mice from both models were dosed orally 
for 6 to 10 days with one of several antiretroviral regimens (table S4). 
In addition, male rhesus macaques (Macaca mulatta) were dosed 
for 10 days with tenofovir and emtricitabine (both subcutaneously) 
and orally with either maraviroc + atazanavir or efavirenz + ralte­
gravir. Antiretroviral doses, routes of administration, and duration 
of therapy were chosen to mimic commonly used treatment doses 
in these models and achieve pharmacokinetic steady­state conditions 
for all agents.
About one­half the animals in each dosing cohort were infected 
with HIV (humanized mice) or SHIV (macaques) to assess the rela­
tionship between antiretroviral tissue disposition and potential 
ongoing HIV infection using HIVBal D7 (hu­HSC­Rag mice), HIVJRcsf 
(BLT mice), or RT­SHIVmac239 (macaques) as previously described 
in detail (18). Animals were euthanized and underwent necropsy 
about 24 hours after the final antiretroviral dose. Plasma was collected, 
and tissues were removed from the body, cut into two about equal­
sized pieces, and snap­frozen on dry ice. All animal experiments were 
performed in accordance with locally approved institutional animal 
care and use committee (IACUC) protocols.
Clinical trial design and subject demographics
This study enrolled five HIV­positive women between 18 and 65 years 
of age (inclusive) with intact gastrointestinal and genital tracts, who 
had undetectable plasma HIV RNA (<50 copies/ml) within 3 months 
preceding the study. Participants were recruited from the Infectious 
Diseases Clinic at University of North Carolina (UNC) Chapel Hill 
on the basis of receiving one of the study regimens (tenofovir diso­
proxil fumarate/emtricitabine as a fixed dose combination plus either 
efavirenz, raltegravir, maraviroc, or atazanavir) as part of their 
ongoing clinical care.
Subjects could not have a history of gastrointestinal disease (e.g., 
Crohn’s disease, irritable bowel syndrome, ulcerative colitis, diver­
ticulitis, and colon cancer) or have a history of gastrointestinal surgery. 
All subjects had a negative serum pregnancy test at screening and 
negative urine pregnancy tests on days of sampling and used at least 
one of the following methods of contraception from the screening 
visit through 72 hours before inpatient admission (at which time 
the women were asked to remain abstinent until after their follow­up 
visit): systemic hormonal contraceptive (oral, depot, transdermal, 
or implant), intrauterine device (IUD) placed at least 1 month be­
fore study enrollment, bilateral tubal ligation (sterilization), vasec­
tomized male partners, or condom with spermicide.
Additional inclusion criteria included BMI of about 18 to 37 kg/m2, 
a total body weight of >45 kg (99 lbs), and evidence of a personally 
signed and dated informed consent document indicating that the 
subject has been informed of all pertinent aspects of the trial and was 
willing and able to comply with scheduled visits, treatment plan, 
laboratory tests, and other trial procedures. Further, women could not be 
receiving any known CYP3A4 inducers (rifampin, carbamazepine, and 
St. John’s wort) or inhibitors [ketoconazole, non–dihydropyridine 
(DHP) calcium channel blockers, and macrolide antibiotics] other 
than those contained in their HIV regimen for at least 6 months 
before enrollment. Subjects had to be willing to abstain from sexual 
intercourse, douching, and all intrarectal objects and products for 
at least 72 hours before enrollment until study completion; have a 
negative hepatitis B surface antigen test as documented on screening 
laboratories; could not be actively involved in the conception process; 
were able to swallow pills; and have no allergies to any component 
of the study products (i.e., bowel preparation regimen).
Participants were excluded if they had any clinically relevant 
abnormal screening evaluations or relevant comorbidities, untreated 
sexually transmitted infections (rectal chlamydia or gonorrhea, syphilis, 
and trichomonas), were pregnant or lactating, or tested positive for 
any drugs of abuse that would increase study risks. Additional ex­
clusion criteria included receiving CYP3A4 inducers or inhibitors 
(other than those contained in their HIV regimens) in the previous 
6 months, receiving any investigational drug in the last 4 months, 
history of inflammatory bowel conditions (Crohn’s disease), or not 
using an approved method of contraception (systemic hormonal 
contraception, IUD, bilateral tubal ligation, vasectomized male 
partner, condom plus spermicide, female­only sex partners, or 3 months 
of abstinence before enrollment).
Further, subjects were excluded if they had a history of febrile 
illness within 5 days before enrollment, active hepatitis B infection 
as determined by positive hepatitis B surface antigen (HBsAg), any 
laboratory chemistry or hematology result grade 3 or greater according 
to the Division of AIDS (DAIDS) Laboratory Grading Tables, history 
of regular alcohol consumption exceeding 14 drinks [1 drink = 5 ounces 
(150 ml) of wine or 12 ounces (360 ml) of beer or 1.5 ounces (45 ml) of 
spirits] per week, participation in a clinical trial involving rectal 
biopsies within 6 months preceding enrollment, blood donation of 
about 1 pint (500 ml) within 56 days before dosing, history of sensitiv­
ity to heparin or heparin­induced thrombocytopenia, or allergy to 
latex or was unwilling or unable to comply with the dietary and 
concomitant drug restrictions in regard to study drug administra­
tion as outlined in the study procedures and prohibited medication 
sections. All study activities were approved by the UNC Biomedical 
Institutional Review Board, and all activities were conducted in 
accordance with all International Council for Harmonisation of 
Technical Requirements for Pharmaceuticals for Human Use (ICH) 
and Good Clinical Practice (GCP) industry standards. All partici­
pants provided written informed consent before study procedures 
were performed.
After participant education, informed consent, and screening for 
study eligibility, participants were assigned to the treatment arm 
associated with the HIV regimen they were receiving. Within 42 days 
of screening, participants were admitted to the NC Translational 
and Clinical Sciences Institute (NC TraCS) Clinical and Translational 
Research Center (CTRC) for a 36­hour inpatient sampling visit. For 
the 7 days before admission, participants were asked to follow a strict 
low­fiber diet in preparation for a colonoscopy. Once admitted, 
participants were given only clear liquids until becoming NPO 
(nothing by mouth) 4 hours before the scheduled colonoscopy. 
Bowel preparation included an oral laxative (two 5­mg bisacodyl 
tablets) followed by 227.1 g of polyethylene glycol 3350 in a 1­gallon 
solution (GoLYTELY). The preparation was divided into two separate 
2­hour blocks: the first beginning 18 hours before the scheduled
procedure and the second half beginning 6 hours before the procedure. 
Before the procedure, a single 3­ml paired blood sample was taken 
and processed for plasma. During the procedure, 10 biopsies each 
were taken from the terminal ileum and rectum. Subjects were 
monitored for 6 hours after the procedure, before discharge, with 
follow­up visits within 14 days of discharge. An analysis of previous 
studies from our group in subjects receiving raltegravir or darunavir 
who underwent similar procedures showed an about 30% decrease 
in both gut tissue and plasma concentrations (as measured by tradi­
tional LC­MS) versus subjects who had not received a complete 
bowel preparation.
Safety assessments were conducted on each day of the inpatient 
visit and during follow­up. Adverse events were evaluated using a 
standard questionnaire, with grading according to the DAIDS ad­
verse events grading table version 2.0. Women of childbearing po­
tential were screened for pregnancy at each visit.
Human tissue collection
Ileal and rectal biopsies were collected during colonoscopy with Radial 
Jaw 4 large capacity biopsy forceps (Boston Scientific, Boston, MA). 
All tissues were immediately snap­frozen on dry ice, then placed in 
aluminum foil pouches, and stored at −80°C until analysis. Whole 
blood was collected in 3­ml EDTA tubes and centrifuged at 3000 rpm 
for 10 min at 4°C. Plasma was aliquoted into a 2­ml cryovial and 
stored at −80°C until analysis.
Tissue slices
To generate serial sections for multimodal analysis, tissues were 
sliced frozen at 10­m thickness using a cryostat (Leica Biosystems, 
Wetzlar, Germany) and thaw­mounted onto glass microscope 
slides in the following order: 8 slices for IHC, 2 slices for MSI (1 for 
analysis and 1 backup), 2 slices for LC­MS, and 15 to 20 slices for 
ISH. Macaque tissues were mounted on optimal cutting temperature 
(OCT) compound and sliced individually; however, the small size 
of the mouse tissues and human biopsies (2­ to 5­mm cross sections) 
precluded this method. Instead, tissues were grouped by dosing 
cohort and mounted within a 2:1 gelatin carboxymethylcellulose 
gel block, which was snap­frozen and stored at −80°C. Dosing 
groups for mice each contained n = 6, and six tissues were included 
in a single gelatin block (e.g., six ileums from the atazanavir­only 
dosing group in a single block and six rectums from the atazanavir­ 
only dosing group in a single gelatin block). For the human samples, 
ileum and rectum from all five women were included in single 
blocks (one block for ileum and one block for rectum). Each frozen 
gel block was mounted on OCT, sliced, and thaw­mounted, allowing 
for mounting and analysis of up to six mouse tissues simultaneously 
(51). Analysis of embedded and non­embedded tissues suggests that 
the gel embedding process does not alter antiretroviral distribution 
within tissues (fig. S1).
MSI and quantification
The glass microscope slide containing the thaw­mounted tissue was 
placed into the IR­MALDESI MSI source chamber and maintained 
at −10°C. Relative humidity inside the chamber was reduced to <6% 
to allow for sample cooling without condensation of water vapor, 
and then humidity was increased to deposit a layer of ice across the 
entire stage. Tissues were ablated with two pulses of a mid­IR laser 
(IR­Opolette 2371, Opotek, Carlsbad, CA) with a 100­m spot­to­
spot distance. Ablated molecules were ionized by orthogonal electro­
spray using 0.2% formic acid in 50:50 methanol water as an electrospray 
solvent and sampled into a Thermo Fisher Scientific Q Exactive 
mass spectrometer (Bremen, Germany) for analysis in positive ion 
mode. Because the detection of certain analytes (e.g., tenofovir and 
efavirenz) was found to be increased in humans by probing for neg­
ative ions, polarity switching was used during these experiments 
using 5 mM ammonium acetate in 50:50 methanol water as the 
electrospray solvent. Raw data from each voxel were converted to 
the mzML format with MSConvert (ProteoWizard) and then to the 
imzML format for interrogation using MSiReader, which allows for 
generation of images of antiretroviral distribution across the tissue 
slice (52, 53).
Absolute quantitation of antiretroviral concentration was achieved 
by spotting a series of calibration standards (of known antiretroviral 
concentration) onto a nondosed “blank” tissue slice from identical 
tissue matrices from each species (ileum or rectum; Bioreclama­
tionIVT, Baltimore, MD). Each calibration standard (100 nl) was 
spotted onto the tissue, allowed to air dry, then placed inside the 
source chamber, and analyzed in an identical manner to the samples. 
A new calibration tissue was analyzed every day that sample analysis 
occurred to account for interday variability in run conditions (electro­
spray stability, relative humidity, thickness of ice layer, etc.). Calibration 
tissues were analyzed in MSiReader, where the summed voxel inten­
sity over each calibration spot was plotted against the known anti­
retroviral concentration to generate a calibration curve. The slope 
and intercept of this curve was applied to the summed voxel intensity 
value for each antiretroviral over the entire area of the correspond­
ing sample to generate an absolute concentration (15). To quantify 
antiretroviral concentration in mouse tissues, a single calibration 
spot was applied to a blank mouse tissue and analyzed in tandem 
with macaque calibration tissues. The voxel intensity value for the 
mouse calibration spot was used to adjust the slope and intercept of 
the NHP calibration curve (to account for response differences 
between tissues from different species), and the adjusted calibration 
curve was applied to mouse samples. Resulting ng/slice concentra­
tions were converted to g/g using the known area of each tissue 
slice measured in MSiReader, depth of each tissue (10 m), and an 
assumed tissue density of 1.06 g/ml.
For the purposes of inclusion in this manuscript, “representative” 
tissue sections were selected primarily on the basis of morphology, 
slice quality, and quality of IR­MALDESI image. For example, 
when possible, we include tissue slices that show a complete cross 
section from gut lumen through the muscularis, with minimal tissue 
folding or tearing in the IHC or ISH slice. However, our results 
are based on analysis of all slices analyzed regardless of aesthetics, 
and we report descriptive statistics (median and range) for all 
variables. To assess interslice variability, we a priori took multiple 
consecutive slices from each tissue for IR­MALDESI analysis, with 
the idea that several backup slices would be available in the event 
of experimental error. Several of these backup slices were analyzed 
and compared to the original data, with good qualitative correla­
tion in distribution.
LC-MS analysis and comparison to MSI
Plasma and tissue antiretroviral quantification of each sample was 
performed using LC­MS methods as described previously (19). 
Plasma samples, calibration standards, and quality control samples 
underwent protein precipitation followed by LC­MS/MS. Internal 
standard was added to plasma and mixed with 600 l of acetonitrile. 
Samples were vortexed and centrifuged, and then the supernatant 
was diluted with 50:50 methanol/water. For tissues, 1 ml of ice­cold 
70:30 acetonitrile/water was added to sample tubes containing a 
serial 10­m section from each sample. Samples were sonicated for 
10 min with calibration standards and quality control samples. Separa­
tion for both matrices occurred on a Shimadzu high­performance 
liquid chromatography system and an AB SCIEX API 5000 mass 
spectrometer (AB SCIEX, Foster City, CA, USA) equipped with a 
turbo spray interface. The dynamic range of the plasma assay ranged 
from 1 to 20,000 ng/ml for tenofovir, atazanavir, and efavirenz; 1 to 
8000 ng/ml for maraviroc; and 8 to 20,000 ng/ml for emtricitabine 
and raltegravir. The dynamic range for tissues is from 0.1 to 50 ng/ml. 
The precision and accuracy of the calibration standards and QC 
samples were within the acceptable range of 15%. Tissue concentra­
tions were reported as ng/slice and converted to g/g using an as­
sumed tissue density of 1.06 g/ml.
Immunofluorescence and IHC
Drug efflux transporter localization was identified using IHC as 
described previously (18). Dual immunofluorescence (IF) on frozen 
humanized mouse and NHP sections was performed on the Bond 
fully automated slide staining system (Leica Microsystems) using 
Bond Polymer Refine Detection kit (DS9800). Slides were allowed 
to sit at room temperature for 30 min and then fixed in 10% formalin 
for 15 min. They were then placed in Bond wash solution (AR9590). 
Antigen retrieval was done at 100°C in Bond epitope retrieval solu­
tion 2 (pH 9.0; AR9640) for 10 min. Staining was performed first 
using CD4 1F6 antibody (clone BC/1F6, Abcam) at 1:50 dilution for 
1 hour with Bond polymer and post­primary reagents and Cy5 fluo­
rochrome (PerkinElmer) for 15 min. Antigen retrieval was done at 
again 100°C in Bond epitope retrieval solution 2 (pH 9.0; AR9640) 
between protocols. Slides were then stained with CD3 (clone LN10, 
Leica) Ready­to­Use antibody for 15 min and Dako Envision mouse 
secondary for 30 min. Cy3 fluorochrome (PerkinElmer) was applied for 
15 min. IF slides were counterstained with Hoechst 33258 (Invitrogen, 
Carlsbad, CA) and mounted with ProLong Gold antifade reagent 
(P36934, Life Technologies).
In situ hybridization
Fifteen to 20 serial sections from each tissue were evaluated for 
HIV/SHIV RNA expression using RNAscope ISH (54). Before 
beginning the RNAscope procedure, slides were fixed in 4% para­
formaldehyde at 4°C for 15 min followed by dehydration with graded 
ethanol washes (50, 70, and 100% ethanol for 5 min each). Detailed 
methodology for the RNAscope procedure is described elsewhere 
(54). Briefly, slides were boiled to retrieve epitopes in P2 buffer 
(Advanced Cell Diagnostics, ACD) for 30 min followed by peroxi­
dase blocking for 10 min at room temperature, rinsing with double­ 
distilled water, dehydrating with 100% ethanol for 5 min, and then 
air­drying. Slides were then incubated for 10 to 20 min at 40°C with 
protease digestion solution from ACD (P3). After protease diges­
tions, slides were rinsed with double­ distilled water and incubated 
with HIV clade B or SIVmac239 ACD probes for 2 hours at 40°C. Slides 
were then washed in 0.5× ACD wash buffer and incubated in am­
plification reagents according to the RNAscope 2.5 HD detection 
protocol (54). All reagents used in the hybridization process were 
obtained from Advanced Cell Diagnostics (Newark, CA) and used 
according to the manufacturer’s protocol with some minor adapta­
tions (54). After counterstaining slides with hematoxylin, slides 
were mounted in clear mount and coverslipped. Staining was per­
formed on all 15 to 20 slides to ensure detection of positive signal. 
Results were compared across slides, and little variability was 
found. Thus, colocalization was performed using the tissue slice 
most adjacent to the slice used for MSI.
Image colocalization
A schematic of the colocalization workflow is shown in fig. S3. For 
a given sample (fig. S3A), MSiReader was used to export voxel 
intensity matrices for cholesterol, heme, and each antiretroviral of 
interest across the entire tissue slice into MATLAB; IF, ISH, and 
IHC samples were scanned as described above and downsampled 
to match the resolution of the MSI data (fig. S2). Off­tissue re­
sponse was eliminated by using cholesterol signal to mask anti­
retroviral response such that only on­tissue signal was shown. To 
eliminate the confounding effect of antiretrovirals contained with­
in the vasculature, antiretroviral responses were again masked on 
the basis of heme distribution (fig. S3B) to show only the anti­
retroviral signal that localized outside the microvasculature. To 
ensure that MSI­derived images and IF/IHC/ISH images were 
appropriately aligned before colocalization, co­registration was per­
formed by rigid transformation of the moving cholesterol image 
using the background 4′,6­diamidino­2­phenylindole (DAPI) stain 
as a fixed reference (fig. S3C). The resulting transform matrix was 
then applied to all antiretroviral images so that every antiretroviral 
image was identically oriented. Last, the heme­corrected trans­
formed antiretroviral images were overlayed with the variable of 
interest (CD3, MDR1, etc.) to generate a fused image (fig. S3D) 
containing both the antiretroviral (in red) and the variable of 
interest (in green).
To evaluate concentrations proximate to relevant variables, 
antiretroviral intensity from a given voxel was multiplied by the total 
slice concentration determined from the quantitative experiments 
and corrected on the basis of the proportional contribution of that 
voxel to the total antiretroviral signal detected in the slice. Descriptive 
statistics (median and range) were generated on the basis of these 
per­voxel antiretroviral concentrations for areas of colocalization 
with the variable of interest (CD3, RNA, etc.). Per­voxel concentra­
tions were then thresholded on the basis of the maximum in vitro 
IC90 value reported in the package insert for each drug to generate 
binary images, showing antiretroviral concentration above and 
below the IC90 value. Where ranges of IC90 values could be found, 
we used the highest value to provide conservatives estimates of 
adequate antiretroviral exposure.
Statistical analysis
Descriptive statistics (median, range) of plasma and tissue drug 
concentrations as well as correlation coefficients were generated for 
each drug in humanized mice and NHPs. Pearson correlation was 
used to assess potential effects of drug efflux transporter expression 
on antiretroviral drug distribution. Sample sizes were chosen to 
provide n = 6 for each animal dosing group, providing statistical 
power to detect 15% differences in antiretroviral drug penetration 
between groups. Because of evolving drug treatment regimens among 
our clinic population, we did not meet our recruitment goal of n = 6 
for each treatment group in the clinical study and thus did not meet 
our prespecified power requirement. Comparisons between animal 
models and between anatomical compartments were performed using 
Kruskal­Wallis analysis of variance (ANOVA) on ranks. P < 0.05 
was considered statistically significant.
SUPPLEMENTARY MATERIALS
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Fig. S1. Effect of gelatin embedding on antiretroviral drug distribution.
Fig. S2. Resolution matching of microscopy and MSI data.
Fig. S3. Image colocalization workflow.
Table S1. Subject demographics.
Table S2. Human plasma and tissue antiretroviral drug concentrations.
Table S3. Proportion of CD3+ T cells exposed to at least one antiretroviral drug.
Table S4. Dosing of animals.
Data file S1. Individual-level data for tables.
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